Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO Thoughts on where this is headed? | Pisd | investorshub | 09/23/2023 3:31:06 AM |
Anyone hear anything lately? Want to see this one go | Anita Dump | investorshub | 09/23/2023 1:46:02 AM |
The now | mfayman | investorshub | 09/23/2023 1:01:05 AM |
MomentumIts trading | ErnieBilco | investorshub | 09/22/2023 11:39:49 PM |
great news | Ryguy008 | investorshub | 09/22/2023 10:44:00 PM |
Do we have a winner?Turn around time? | mfayman | investorshub | 09/22/2023 10:31:39 PM |
$OKYO MomentumIts trading last trade up | Sirpeter | investorshub | 09/22/2023 9:25:31 PM |
$OKYO are we finally gonna see some action | Count Crypto | investorshub | 09/22/2023 9:14:39 PM |
good read | Ryguy008 | investorshub | 09/22/2023 8:48:54 PM |
$OKYO Price trading last up | Sirpeter | investorshub | 09/22/2023 6:27:54 PM |
$OKYO are we finally gonna see some action | mfayman | investorshub | 09/22/2023 5:45:15 PM |
$OKYO MomentumIts trading last trade up | Pisd | investorshub | 09/22/2023 4:05:14 PM |
$OKYO Do we have a winner?Turn around time? | mfayman | investorshub | 09/22/2023 2:54:58 PM |
The trading last up | Count Crypto | investorshub | 09/22/2023 2:13:36 PM |
$OKYO Found an interesting article | Pisd | investorshub | 09/22/2023 1:51:45 PM |
$OKYO The now | StocksNcash | investorshub | 09/22/2023 1:25:50 PM |
$OKYO The now | Count Crypto | investorshub | 09/22/2023 11:26:18 AM |
$OKYO bulls and bears | Boris the Spider | investorshub | 09/22/2023 11:06:28 AM |
$OKYO news out | Count Crypto | investorshub | 09/22/2023 10:56:57 AM |
Price trading | mfayman | investorshub | 09/22/2023 10:19:08 AM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...